EE200100662A - Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine - Google Patents

Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine

Info

Publication number
EE200100662A
EE200100662A EEP200100662A EEP200100662A EE200100662A EE 200100662 A EE200100662 A EE 200100662A EE P200100662 A EEP200100662 A EE P200100662A EE P200100662 A EEP200100662 A EE P200100662A EE 200100662 A EE200100662 A EE 200100662A
Authority
EE
Estonia
Prior art keywords
preparation
therapeutic use
anticoagulant compound
pharmaceutical preparation
preparation containing
Prior art date
Application number
EEP200100662A
Other languages
English (en)
Inventor
Klingler Otmar
Schudok Manfred
Zoller Gerhard
Heinelt Uwe
Defossa Elisabeth
Matter Hans
Safar Pavel
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200100662A publication Critical patent/EE200100662A/et
Publication of EE04855B1 publication Critical patent/EE04855B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200100662A 1999-06-08 2000-05-27 Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine EE04855B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99111109A EP1059302A1 (en) 1999-06-08 1999-06-08 Factor VIIa inhibitors
PCT/EP2000/004846 WO2000075172A2 (en) 1999-06-08 2000-05-27 FACTOR VIIa INHIBITORS

Publications (2)

Publication Number Publication Date
EE200100662A true EE200100662A (et) 2003-04-15
EE04855B1 EE04855B1 (et) 2007-06-15

Family

ID=8238315

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100662A EE04855B1 (et) 1999-06-08 2000-05-27 Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine

Country Status (32)

Country Link
US (1) US6500803B1 (et)
EP (2) EP1059302A1 (et)
JP (1) JP4546683B2 (et)
KR (1) KR100979069B1 (et)
CN (1) CN1359390B (et)
AR (1) AR024292A1 (et)
AT (1) ATE246707T1 (et)
AU (1) AU774037B2 (et)
BR (1) BR0011461A (et)
CA (1) CA2376064C (et)
CZ (1) CZ300365B6 (et)
DE (1) DE60004363T2 (et)
DK (1) DK1189929T3 (et)
EE (1) EE04855B1 (et)
ES (1) ES2202137T3 (et)
HK (1) HK1047289B (et)
HR (1) HRP20010912B1 (et)
HU (1) HUP0201451A3 (et)
IL (2) IL146731A0 (et)
ME (1) MEP57708A (et)
MX (1) MXPA01012568A (et)
NO (1) NO328249B1 (et)
NZ (1) NZ515966A (et)
PL (1) PL202879B1 (et)
PT (1) PT1189929E (et)
RS (1) RS50415B (et)
RU (1) RU2248359C2 (et)
SI (1) SI1189929T1 (et)
SK (1) SK286902B6 (et)
TR (1) TR200103550T2 (et)
WO (1) WO2000075172A2 (et)
ZA (1) ZA200110053B (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
JP4179878B2 (ja) * 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
GB0127615D0 (en) 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
CA2536073A1 (en) 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
DK3993876T3 (en) 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
AU2022205313A1 (en) 2021-01-06 2023-07-20 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA953361B (en) * 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
ES2186874T3 (es) * 1996-02-22 2003-05-16 Bristol Myers Squibb Pharma Co Analogos de m-amidinofenilo como inhibidores del factor xa.
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors

Also Published As

Publication number Publication date
SK17592001A3 (sk) 2002-05-09
HUP0201451A2 (en) 2002-08-28
DE60004363T2 (de) 2004-06-24
SK286902B6 (sk) 2009-07-06
ATE246707T1 (de) 2003-08-15
JP2003502294A (ja) 2003-01-21
AR024292A1 (es) 2002-09-25
WO2000075172A3 (en) 2001-05-31
KR100979069B1 (ko) 2010-08-31
PT1189929E (pt) 2003-12-31
PL352200A1 (en) 2003-08-11
EP1189929B1 (en) 2003-08-06
CZ20014357A3 (cs) 2002-03-13
ES2202137T3 (es) 2004-04-01
US6500803B1 (en) 2002-12-31
IL146731A0 (en) 2002-07-25
AU5397600A (en) 2000-12-28
NO20016005D0 (no) 2001-12-07
EP1189929A2 (en) 2002-03-27
CA2376064C (en) 2011-04-26
SI1189929T1 (en) 2004-02-29
CA2376064A1 (en) 2000-12-14
JP4546683B2 (ja) 2010-09-15
ZA200110053B (en) 2002-07-03
NZ515966A (en) 2003-09-26
RS50415B (sr) 2009-12-31
CZ300365B6 (cs) 2009-04-29
NO20016005L (no) 2002-02-06
PL202879B1 (pl) 2009-07-31
HRP20010912B1 (en) 2010-10-31
EE04855B1 (et) 2007-06-15
HUP0201451A3 (en) 2003-08-28
EP1059302A1 (en) 2000-12-13
AU774037B2 (en) 2004-06-17
HK1047289A1 (zh) 2003-02-14
TR200103550T2 (tr) 2002-05-21
HK1047289B (zh) 2010-10-22
RU2248359C2 (ru) 2005-03-20
IL146731A (en) 2007-07-24
BR0011461A (pt) 2002-03-19
DE60004363D1 (de) 2003-09-11
MXPA01012568A (es) 2002-04-10
WO2000075172A2 (en) 2000-12-14
YU86101A (sh) 2004-07-15
CN1359390B (zh) 2010-05-26
NO328249B1 (no) 2010-01-18
CN1359390A (zh) 2002-07-17
MEP57708A (en) 2011-05-10
KR20020020728A (ko) 2002-03-15
DK1189929T3 (da) 2003-11-24
HRP20010912A2 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
EE03613B1 (et) Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
DE60043305D1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EE200100572A (et) 1-(p-tienüülbensüül)imidasool, seda sisaldav farmatseutiline preparaat ja nende raviotstarbeline kasutamine
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
NO20006630L (no) Farmasöytisk sammensetning for behandlingen av diabetes
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
ITMI991817A0 (it) Compositi farmaceutici
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
DE60010464D1 (de) Geschmackskaschierte flüssige arzneizubereitungen
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20020531D0 (no) Beta-carbolin medikament produkter
EE04855B1 (et) Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
FR2791059B1 (fr) Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
EE05175B1 (et) Asendatud bensimidasooli preparaat, meetod selle valmistamiseks ja selle kasutamine meditsiinis
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130527